|
|
|
| Efficacy of Dexamethasone combined with Ursodeoxycholic Acid in Clinical treatment of Intrahepatic Cholestasis of Pregnancy and its Effects on Level of PLTP IL-18 |
| LI Hua, ZHANG Liping, GAO Xia, et al |
| The Affiliated Hospital of Yan'an University, Shaanxi Yan'an 716000, China |
|
|
|
|
Abstract Objective: To study curative efficacy of dexamethasone combined with ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy and its effects on level of PLTP,IL-18. Methods: 130 patients with intrahepatic cholestasis of pregnancy treated in our hospital from Oct. 2014 to Oct. 2016 were selected and divided into the observation group and the control group according to different treatment methods. The patients in observation group were treated with dexamethasone and deoxycholic acid, while the patients in control group were treated with dexamethasone. Then the clinical effect, serum levels of PLTP and IL-18, pruritus score and pregnancy outcomes in the two groups were observed and compared before and after the treatment. Results: After treatment, the total efficacy of observation group was 93.8%, which was obviously higher than that of the control group (80.0%, P<0.05); After treatment, the serum levels of PLTP and IL-18 in the observation group were significantly lower than those of the control group (3.17±0.33) pg/mL vs (4.47±0.49) pg/mL; (58.03±6.02) ng/mL vs (68.86±7.11) ng/mL)(P<0.05); After treatment, the levels of ALT, AST and TBIL, and pruritus score of observation group were significantly lower than those of the control group(P<0.05). There was no statistically significant difference in the incidence of premature birth, fetal distress and neonatal asphyxia between the two groups (P>0.05). The cesarean section rate in the observation group was significantly lower than that of the control group, and the apgar score was higher (P<0.05). Conclusion: The clinical efficacy of dexamethasone combined with ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy is significantly better than that of dexamethasone alone. It can effectively improve the liver function and pregnancy outcome, and reduce the level of serum PLTP and IL-18.
|
|
|
|
|
|
[1] Keitel V, Droge C, Stepanow S, et al. Intrahepatic cholestasis of pregnancy (ICP): case report and review of the literature[J]. Gastroenterol, 2016,54(12):1327~1333.
[2] He Y, Zhang L, Zhu Z, et al. Blockade of cyclophilin D rescues dexamethasone-induced oxidative stress in gingival tissue[J]. PLoS One, 2017 ,12(3):e0173270.
[3] 赵薇, 王玫,任景芳.地塞米松联合思美泰、熊去氧胆酸治疗妊娠期肝内胆汁淤积症疗效观察[J].现代中西医结合杂志,2015,v.24(20):2240~2242.
[4] 贺晶,杨慧霞,段涛,等.妊娠期肝内胆汁淤积症诊疗指南(2015)[J].临床肝胆病杂志,2015,31(10):1575~1578.
[5] 中华医学会妇产科学分会产科学组.妊娠期肝内胆汁淤积症诊疗指南(第1版)[J].中华妇产科杂志,2011,46(5):391~395.
[6] Furrer R, Winter K, Schaffer L, et al. Postpartum blood loss in women treated for intrahepatic cholestasis of pregnancy[J]. Obstet Gynecol, 2016,128(5):1048~1052.
[7] 谭白菊,李玉梅,冯小平,等.丁二磺酸腺苷蛋氨酸联合地塞米松对妊娠期肝内胆汁淤积症患者免疫功能及疗效的影响[J].国际妇产科学杂志,2016,43(5):563~566.
[8] Fukui T, Nakamura K, Sakatani T, et al.Low-dose estramustine phosphate monotherapy in castration-resistant prostate cancer patients[J]. Hinyokika Kiyo, 2017,63(2):57~62.
[9] 杨红英,徐晓青,朱珺熙,等.熊去氧胆酸联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症的临床分析[J].重庆医学,2016,45(20):2845~2847.
[10] 申铁英,郭秀云,罗万翠.地塞米松联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症的疗效及对患者肝功能、炎性细胞因子水平的影响[J].中国妇幼保健,2017,32(18):4333~4336.
[11] Brzozowska M, Kowalska-Koprek U, Karowicz-Bilinska A. Influence of pharmacological treatment on selected parameters of intrahepatic cholestasis of pregnancy[J]. Ginekol Pol,2010, 81(2):94~98.
[12] 张建梅,洪博,徐硕.熊去氧胆酸联合S-腺苷蛋氨酸改善妊娠期肝内胆汁淤积症临床疗效及对患者血清中磷脂转运蛋白、白细胞介素1表达水平的影响[J].中国临床医生杂志,2016,44(9):87~89.
[13] 张莉,李晓丽,兰远霞.妊娠期肝内胆汁淤积症孕妇血液流变学、凝血功能和细胞因子的变化及临床意义[J].海南医学院学报,2015,21(8):1088~1090.
[14] Lana JP, Martins LB, Oliveira MC, et al. TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions[J]. Appl Physiol Nutr Metab, 2016,41(12):1295~1302. |
|
|
|
2018, Vol. 24 
